1. Home
  2. AAP vs ACAD Comparison

AAP vs ACAD Comparison

Compare AAP & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Advance Auto Parts Inc.

AAP

Advance Auto Parts Inc.

HOLD

Current Price

$55.80

Market Cap

3.6B

ML Signal

HOLD

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$24.84

Market Cap

4.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AAP
ACAD
Founded
1929
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Auto & Home Supply Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
4.3B
IPO Year
2002
2000

Fundamental Metrics

Financial Performance
Metric
AAP
ACAD
Price
$55.80
$24.84
Analyst Decision
Hold
Buy
Analyst Count
17
22
Target Price
$53.50
$30.55
AVG Volume (30 Days)
1.8M
1.7M
Earning Date
05-21-2026
05-06-2026
Dividend Yield
1.79%
N/A
EPS Growth
113.01
69.12
EPS
0.39
0.02
Revenue
$8,601,000,000.00
$726,437,000.00
Revenue This Year
$0.35
$18.80
Revenue Next Year
$2.51
$11.70
P/E Ratio
$136.97
$1,241.50
Revenue Growth
N/A
40.45
52 Week Low
$37.89
$19.69
52 Week High
$65.21
$28.35

Technical Indicators

Market Signals
Indicator
AAP
ACAD
Relative Strength Index (RSI) 46.89 51.72
Support Level $54.63 $20.56
Resistance Level $61.73 $25.36
Average True Range (ATR) 2.68 0.76
MACD -0.16 -0.26
Stochastic Oscillator 46.13 23.84

Price Performance

Historical Comparison
AAP
ACAD

About AAP Advance Auto Parts Inc.

Advance Auto Parts is a leading auto-parts retailer in North America with more than 4,000 store and branch locations. About half of the firm's sales are geared toward the professional channel, with the remaining sales in the do-it-yourself market. Through its vast store footprint and distribution network, Advance manages thousands of stock-keeping units for various vehicle makes and models. The retailer primarily competes on inventory availability and service speed, making the operating efficiency of its hub-and-spoke distribution model critical to meeting customer needs.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: